Posterior chamber toric phakic intraocular lenses for myopic astigmatism: first experience in India.
To evaluate the efficacy and safety of the toric Implantable Collamer Lens phakic intraocular lens (pIOL) in the management of myopic astigmatism in Indian eyes. Tertiary eyecare center, South India. Retrospective interventional case series. The study included consecutive patients with myopic astigmatism with a minimum follow-up of 1 year. Safety, efficacy, predictability, and adverse events were assessed preoperatively and 12 months postoperatively. The study enrolled 110 eyes (65 patients). The mean corrected distance visual acuity was 0.23 logMAR ± 0.23 (SD) preoperatively and 0.18 ± 0.18 logMAR 12 months postoperatively (P<.001). The mean refractive cylinder decreased from 2.3 ± 1.1 diopters (D) to 0.4 ± 0.6 D, respectively (P<.001). Postoperatively, the uncorrected distance visual acuity improved to 20/20 in 15 eyes (13.6%) and 20/40 or better in 72 eyes (65.4%). Fourteen eyes (12.7%) gained 2 or more lines of corrected distance visual acuity, 21 eyes (19.1%) gained 1 line, 61 eyes (55.5%) had no change, and 1 eye (0.9%) lost 2 lines. Predictability within ±0.50 D of cylinder was achieved in 77 eyes (70 %) and within ±1.00 D in 97 eyes (88.2%). Twelve months postoperatively, the safety index was 0.75 and the efficacy index was 1.04. Endothelial cell loss at the end of 12 months was 10.3%. Clinically significant cataract developed in 1 eye (0.9%). Implantation of posterior chamber toric pIOLs to correct myopic astigmatism was effective, safe, and predictable.